Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Insilico Medicine Cayman TopCo’s wholly owned subsidiary, Insilico Medicine Ltd., entered a strategic drug-discovery collaboration with Luoxin Pharmaceuticals. * The partnership will prioritize AI-powered research into digestive, metabolic and other non-oncology chronic diseases. * Specific projects remain subject to negotiation and definitive agreements, with implementation planned in phases. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261113-12411853), on November 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.